A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers

. Author manuscript; available in PMC: 2018 Mar 1.

Published in final edited form as: Gynecol Oncol. 2017 Jan 18;144(3):486–490. doi: 10.1016/j.ygyno.2017.01.016

Figure 1. Progression-free survival (PFS) and overall survival (OS): all ovarian cancer patients by platinum-sensitivity status.